
Precigen (PGEN) Stock Forecast & Price Target
Precigen (PGEN) Analyst Ratings
Bulls say
Precigen Inc. is poised for potential growth due to the anticipated approval of PRGN-2012, which is expected to establish itself as a leading therapy for recurrent respiratory papillomatosis (RRP), likely increasing awareness and improving diagnostic rates. The strong clinical results, which indicate significant reductions in the need for surgeries among patients, suggest that PRGN-2012 may achieve widespread acceptance among specialists in the field. The company's confidence in obtaining regulatory approval by the August 27, 2025 PDUFA date further underlines its strategic positioning for future commercial success within the biopharmaceutical market.
Bears say
Precigen Inc faces significant challenges in maintaining or growing sales of its existing products due to a competitive market environment and pricing pressures that could jeopardize revenue stability. Furthermore, the company has a history of financial losses and lacks a consistent profitability track record, raising concerns about its long-term financial health. Additionally, the risk associated with its balance sheet underscores potential vulnerabilities that may impact its operations and investment appeal.
This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.
Precigen (PGEN) Analyst Forecast & Price Prediction
Start investing in Precigen (PGEN)
Order type
Buy in
Order amount
Est. shares
0 shares